Background: Some patients diagnosed with early-stage lung cancer and treated according to standard care survive for only a short period of time, while others survive for years for reasons that are not well understood. Associations between markers of inflammation and survival from lung cancer have been observed.
(short survivors, SS) or >156 weeks (3 years) (long survivors, LS) were selected from a retrospective population-based study. Logistic regression was used to calculate adjusted odds ratios (ORs) and corresponding 95% confidence intervals (CIs). The false discovery rate was calculated to adjust for multiple testing.
Results: A total of 157 LS and 84 SS were included in this analysis. Thirteen markers had adjusted OR on the order of 2-to 5-fold when comparing the upper and lower quartiles with regard to the odds of short survival versus long. Chemokine CCL15 [chemokine (C-C motif ) ligand 15] was the most significant marker associated with increased odds of short survival (ORs = 4.93; 95% CI 1.90-12.8; q-value: 0.042). Smoking and chronic obstructive pulmonary disease were not associated with marker levels.
Conclusions:
Our results provide some evidence that deregulation of inflammatory responses may play a role in the survival of early-stage lung cancer. These findings will require confirmation in future studies. Key words: CCL15, inflammatory markers, lung cancer, survival introduction Lung cancer is the leading cause of cancer death worldwide [1] . About 15% of lung cancers are diagnosed at early stages when the disease is more likely to be successfully treated [2] . But even in those patients diagnosed with early-stage lung cancer who receive optimal treatment, survival remains poor [2] . Treatment guidelines and prognosis are strongly based on disease stage at the time of diagnosis. Among those diagnoses with early-stage disease and treated by standard approaches, there is substantial heterogeneity in patient survival outcomes for reasons that are not well understood [3] [4] [5] . The identification of markers that reveal the underlying mechanisms related to survival from early-stage disease could aid in the development of new therapies.
Evidence from epidemiological and clinical studies suggests that inflammatory diseases of the lung, such as chronic obstructive pulmonary disease (COPD) or asbestosis, increase the risk of lung cancer mortality [6] [7] [8] . Similarly, smoking, also associated with poor survival after lung cancer diagnosis [9] [10] [11] , is thought to alter the inflammatory microenvironment of the lung [12] [13] [14] . Genetic and molecular evidence has added support to the association between inflammation and lung cancer survival. Several studies have reported associations between single nucleotide polymorphisms in immune-related genes and survival in lung cancer [15] [16] [17] [18] [19] . Gene expression of 11 cytokines was capable of identifying a group of patients with poor survival in lung adenocarcinoma patients in a different study [20] . Elevated preoperative serum levels of several inflammatory markers such as basic fibroblast growth factor, an angiogenic cytokine, interleukin-6 (IL-6), a proinflammatory cytokine, or angiogenic CXC chemokines have been associated with poor outcomes [21] [22] [23] [24] . Despite these associations, the studies included subjects with all disease stages who received varied treatments. In addition, studies frequently do not examine whether markers add information beyond standard clinical and pathological variables. Further, only a limited number of markers and their association with survival have been investigated. Multiplex assay platforms enable simultaneous evaluation of a large number of inflammatory circulating markers in small amounts of plasma [25] . Such an approach allows investigators to perform a comprehensive evaluation of the role of circulating levels of inflammatory markers in epidemiologic studies.
Using data and specimens collected in a retrospective population-based study of lung cancer, we carried out assays for immune and inflammatory markers to examine the association between plasma levels of 77 circulating markers and long versus short survival in stage I and II lung cancer patients. Analyses with and without adjustment for standard variables are presented.
methods
The REMARK guidelines [26] were followed, as relevant, for reporting the design, methods, and results of this study.
study population and subject selection
Subjects for this study were a subset of lung cancer patients in the Environment and Genetics in Lung cancer Etiology (EAGLE) study [27] . Briefly, 2100 incident, primary lung cancer cases, ages 35-79 years old, born in Italy, and residents of the Lombardy region, Italy, were recruited for the EAGLE study between 22 April 2002 and 28 February 2005. Computer-assisted personal interviews and self-administered questionnaires were collected from all subjects. All subjects in the study signed an informed consent form, and the study was approved by the Institutional Review Board of each participating hospital and university in Italy and by the U.S. National Cancer Institute. Lung cancer was diagnosed by standard clinical criteria and confirmed by pathology reports from surgery, biopsy, and imaging [27] . Vital status was determined by means of clinical records, the Vital Statistic Office and death certificates through the Local Health Units. The primary end point for this study was death due to any cause. The follow-up time was calculated as the time from diagnosis to the date of death from any cause, loss to follow-up, or 31 December 2010, whichever came first. Funding was obtained to study 249 patients with early-stage lung cancer (I and II according to the 2004 World Health Organization classification of lung tumors [28] ), diagnosed with nonsmallcell lung cancer (NSCLC) (either squamous cell carcinoma or adenocarcinoma of the lung; mixed types and other histologies were excluded). Patients surviving either <79 weeks (∼1.5 years) or >156 weeks (3 years) were selected for this analysis (Figure 1 ). Most nonsmokers with the above characteristics (69.5% of all the available nonsmokers) were included in the analysis, along with a random sample of smokers ( past and current smokers). This sampling design that selects patients at the extremes of the observed survival distribution maximizes the statistical power to detect associations with the markers under the assumption that the relationship between marker levels and survival is monotone. The American Joint Committee on Cancer (AJCC) proposed a new staging classification for lung cancer in 2010 [29] . Based on this new classification, 8 of the 249 subjects (5 surviving <79 weeks and 3 surviving >156 weeks) were reclassified with stage III lung cancer [30] . Data from these eight subjects were excluded from the analyses.
blood samples and laboratory methods
Information on blood samples is provided in Note S1. A total of 77 analytes (supplementary Table S1 , available at Annals of Oncology online) were measured either in a magnetic (n = 61) or polystyrene (n = 16) beadbased assay from Millipore (Billerica, MA) [25] . EDTA plasma specimens (n = 249) were randomly divided into seven different batches for the multiplexed analysis and assayed across 6 panels: 4 cytokine panels, 1 soluble receptor panel (13 analytes), and an acute-phase protein panel (3 analytes). Specimens were assayed in duplicate wells, and the duplicate measurements were averaged. Two recombinant quality control samples supplied with each Millipore kit (QC1 and QC2) were added to each plate to assess batch-to-batch variability (Note S2). Specimens within the acutephase protein panel for batches 1-2 were tested at a 1 : 2000 dilution. However, batches 3-7 were tested at a 1 : 6000 dilution due to a high percentage of specimens from batches 1-2 having values greater than the maximum detectable level for the majority of analytes. Values of the marker CXCL9 for subjects in one batch were excluded from the analysis due to a problematic standard curve. Laboratory personnel performing the assays were blinded to the study end point. Values below the minimum detectable level were assigned half of the minimum level, while those above the maximum detectable level were given the maximum value.
statistical analysis
Marker levels were log-transformed to approximate a normal distribution. A Pearson χ 2 test was used to compare differences in detectability proportions for each marker between long survivors (LS) and short survivors (SS). Median levels of analytes were compared between LS and SS using the Mann-Whitney test. Odds ratios (ORs), defined as the relative odds of being a SS versus a LS, and corresponding 95% confidence intervals (CIs) were estimated using adjusted logistic regression models for the levels of the markers categorized in quartiles (Note S3). Quartiles were defined based on values from the entire group of patients and denoted as Q1 (lowest quartile), Q2, Q3, and Q4 (highest quartile). Trend P-values were the P-values associated with the continuous quartile variable (coded 0, 1, 2, 3) in the regression model. Quartile cuts for CRP, SAA, and SAP were defined based on results from testing batches 3-7 tested at 1 : 6000 dilution as described previously. Nine subjects (five LS and four SS) had neoadjuvant chemotherapy before plasma collection, with the rest of study subjects not receiving chemotherapy before blood draw. Excluding data from these subjects did not substantially change the results and, therefore, they were included in the analyses. Similarly, restricting the analysis to subjects who had surgery did not essentially change our estimates (supplementary Tables S8 and S20 , available at Annals of Oncology online) and, therefore, patients who did not have surgery were not excluded. As a sensitivity analysis, we perform an analysis for patients who did not receive either chemotherapy treatment (neoadjuvant or adjuvant chemotherapy) or radiation therapy to distinguish pure prognostic effects from effects of chemotherapy/radiation treatment on survival. No qualitative differences were found (supplementary Tables S8 and S23 , available at Annals of Oncology online). Because of the large number of markers considered, a false discovery rate (FDR) was used. The FDR is an estimated proportion of false discoveries among the rejected hypotheses. For each test, we present a qvalue, which is the minimum estimated FDR incurred when calling that test significant in the context of all of the tests that were carried out, and it is an FDR analog to the P-value [31] . We focus our discussion on markers with q-values <5%. All analyses were done using the R software package (version 2.13.0). Principal component analysis (PCA) was carried out using the prcomp function in R for purposes of data dimension reduction. The weight (or loading) of each marker with each principal component (PC) was the correlation between the PC and the marker. Q-values were computed using the qvalue library.
results
A total of 241 lung cancer patients, 157 LS and 84 SS, were included in this analysis. The median follow-up time for LS was ∼341 weeks (interquartile range: 289.4-389.1 weeks; Table 1 ) and was ∼45 weeks for SS (interquartile range: 20.6-61.3 weeks). One hundred twenty-two (77.7%) of LS were still alive at the end of the study, 29 (18.5%) died from lung cancer, and 6 (3.8%) died from other causes. Seventy (83.3%) of SS died from lung cancer and 14 (16.7%) died from other causes. Other characteristics of the participants are shown in Table 1 . Specifically, SS were more likely to be older, be diagnosed with stage IB or II lung cancer, currently smoke, have moderate or severe spirometer-based COPD, and not have undergone surgery.
There were no statistically significant differences in marker detectability between LS and SS (supplementary Table S7 , available at Annals of Oncology online). Three markers (IL-1RI, RAGE, and CCL3) had <20% detection rates for both LS and SS (supplementary Table S7 , available at Annals of Oncology online) and were excluded from further analysis. Thirteen markers (CCL15, IL-8, CRP, IL-2Ra, TNF-a, IL-6, IL-6R, CXCL13, TNFRII, CCL19,TNFRI, VEGFR3, and IFN-g) increased the odds of short survival by 2-to 5-fold when comparing Q4 with Q1 (Tables 2, supplementary Table S8 , available at Annals of Oncology online). TRAIL reduced the risk of short survival by 62% when comparing Q4 with Q1. Without correcting for multiple comparisons, eight markers (CCL15, IL-8, CRP, IL-2Ra, TNF-a, IL-6, TRAIL, and IL-6R) had a trend P-value significant at the 5% level. Elevated levels of most markers were associated with increased odds of short survival when comparing Q4 with Q1. Chemokine CCL15 was the most significant marker (OR: 4.93; 95% CI 1.9-12.8). Similar results were observed in the unadjusted analysis (supplementary Table S9 , available at Annals of Oncology online).
The association between circulating markers and several patient/disease variables are presented in supplementary Tables  S2-S6 and S12-S13, available at Annals of Oncology online. A few markers were significantly associated with age, sex, and histology, after adjusting for multiple comparisons. Specifically, higher levels of CXCL9, TNFRII, CCL21, CXCL10, TNFRI, and IL-10 were associated with older ages (q-values: 4.1 × 10 , 0.002, 0.002, 0.020, and 0.032, respectively; supplementary Table S2 , available at Annals of Oncology online). Higher levels of CRP, SAA, IL-6, and TNFRI were associated with the male gender (q-values: 3.2 × 10 −4 , 0.018, 0.020, and 0.025, respectively; supplementary Table S3 , available at Annals of Oncology online) while higher levels of TRAIL were associated with the female gender (qvalue = 0.001; supplementary Table S3 , available at Annals of Oncology online). Finally, higher levels of CCL22 were associated with adenocarcinoma (q-value = 0.026; supplementary Table S6 , available at Annals of Oncology online). Markers were not associated with smoking, stage, or COPD (supplementary Tables S4, S5 , S12, and S13, available at Annals of Oncology online).
Inflammatory marker effects are known to be pleiotropic and redundant. A correlation matrix of the 71 markers, excluding CRP, SAA, and SAP for which we did not have continuous Figure S1 , available at Annals of Oncology online). Correlations ranged from −0.4 to 0.95. To account for these correlations, PCA was conducted. The first PC, which is a linear combination of the markers and accounts for the most variability, captured over 30.7% of the variance, while the second and third components captured ∼7.0% and 6.6% of the variance, respectively (supplementary Figure S2 , available at Annals of Oncology online). Nineteen PCs were needed to account for at least 80% of the variance. PCs were weakly associated with survival (Table 3, supplementary Table S14 , available at Annals of Oncology online). The most significant PCs did not discriminate subjects according to survival status (supplementary Figure S3 , available at Annals of Oncology online). Furthermore, many markers contributed to these PCs without a clear biological interpretation (supplementary Table S15 , available at Annals of Oncology online). PCA did not cluster markers according to age, sex, smoking status, stage, histology, or COPD (supplementary Figure S4 , available at Annals of Oncology online). Finally, we conducted exploratory analyses within subgroups defined by sex, smoking status, stage, histological type, surgery, and COPD (supplementary Tables S16-S22, available at Annals of Oncology online). After adjusting for multiple testing, CCL15 was associated with short survival among those who had surgery (q-value = 0.016; supplementary Table S20 , available at Annals of Oncology online).There was a suggestive association between IL-8 and short survival among Table S14 , available at Annals of Oncology online. b Q-value associated with a particular test measures the minimum false discovery rate that is incurred when calling that tests significant in the context of all tests carried out. *Adjusted for age (continuous), sex, smoking status (never/former/current), pack-years of smoking (continuous), stage (I/II), histology (adenocarcinoma/ squamous cell carcinoma), surgery (yes/no), chemotherapy (yes/no), and radiation (yes/no). 
discussion
Our study evaluated associations of a large number of circulating markers of immunity and inflammation with longversus short-term survival in lung cancer patients diagnosed with stage I and II and NSCLC. After applying a correction for multiple comparisons, chemokine CCL15 significantly increased the odds of short survival by almost 5-fold when comparing Q4 with Q1, after adjustment for standard clinical and pathological characteristics. Seven other markers (IL-8, CRP, IL-2Ra, TNF-a, IL-6, TRAIL, and IL-6R) also significantly increased or decreased the odds of short survival and had significant trend P-values, but with higher q-values that exceeded our cutoff of 0.05.
Chemokine CCL15 is a protein coded in a CC chemokine gene cluster on chromosome 17q. It is chemotactic for T-cells and monocytes [32] , and it mainly acts through chemokine receptor 1 (CCR1) [33] . This chemokine is highly expressed in the lung leukocytes and macrophages [34] . It is also secreted by airway smooth muscle cells, and it has been found to be important in the recruitment of inflammatory cells in asthmatic patients [35] . Recently, it has been observed that this chemokine promotes angiogenesis [36] .
A study of 334 lung cancer patients found that cytokine IL-6 was associated with a significant increased risk of mortality in Caucasians (HR: 1.71; 95% CI 1.22-2.40) comparing levels higher to lower than the median value [23] . Although that study included patients staged I-IV (with ∼50% of them with stages I and II), the analysis was only broadly adjusted for stage (II-IV versus I) [23] . In our study, IL-6 increased the odds of short survival by almost three-fold comparing Q4 with Q1 (OR: 2.84; 95% CI 1.08-7.43), but the difference did not reach statistical significance after adjusting for multiple testing. Although the different sampling schemes in the two studies make it difficult to directly compare the magnitude of the risk associated with higher levels of IL-6, both studies found that higher levels of IL-6 were associated with poor survival.
Previously, it had been reported that a gene expression profile of 11 inflammatory markers (including IL-10, IL-8, IL-6, TNF-a, IL-1a, IL-15, IL-2, and IFN-g) measured in noncancerous lung tissue samples was able to cluster lung adenocarcinoma patients according to outcome [20] . In our study, circulating levels of the markers coded by the above genes were not significantly associated with short survival after correcting for multiple testing (q-value > 0.05). A different study found that levels of CXCL1, CXCL5, IL-8, and VEGF were increased in tumor relative to adjacent, benign lung tissue after resection of lung cancer [24] . Moreover, higher levels of VEGF were associated with recurrence of lung cancer. However, these analyses did not adjust for important potential confounders. In our analysis, circulating levels of CXCL1, CXCL5, IL-8, or VEGF were not associated with short survival. Our results on VEGF were similar to those in a different study [21] .
There are some limitations that could have affected our results. Additional true associations could exist but we may have failed to detect them because of insufficient statistical power. However, the sample size in our study was either comparable (n = 334) [23] or larger (n = 80, 58, 87, [20, 21, 24] , respectively) than in previous ones. Another limitation is that we measured circulating levels of inflammatory markers, which might not be a reflection of the tumor microenvironment, but rather of the systemic state of the patients. The strengths of our study were the rich epidemiological and clinical data, as well as the large number of markers analyzed. In addition, we compared early-stage lung cancer patients at the extremes of the survival distribution to maximize the chance of detecting an association between marker levels and survival. However, this limits the opportunity to assess predictive ability in a clinically interpretable way. Attempting to determine predictors would result in biased estimates of predictor performance. Further studies in a group of patients not selected from the extremes of the outcome distribution would be required to determine whether this chemokine has the capacity to predict outcome beyond what could be predicted by standard demographic, clinical, and pathological characteristics and treatment received.
In summary, in this comprehensive study of circulating levels of immune and inflammatory markers in relation to survival in early-stage lung cancer, chemokine CCL15 was significantly associated with poor survival beyond other demographic, clinical, pathological, and treatment variables. The results provide some evidence that deregulation of inflammatory responses may play a role in the survival of early-stage lung cancer, but these findings will require confirmation in further studies. 
